Dear Mr. Eisgruber, 

We are writing to notify you of recently available information prompting concern that fraud has been committed by Pfizer and by the FDA in the development and continued distribution of  Pfizer’s Covid-19 vaccine. Given that Princeton University mandates Covid-19 vaccination for  students as a condition of enrollment, it is incumbent upon you to be fully informed about the  safety and efficacy of these vaccines and the claims of fraud that call both into question. 

If fraud or willful misconduct is proven, the manufacturers and those involved in the  distribution or mandating of the vaccines will lose immunity from liability granted to them  under the existing EUA and the PREP act.  

We urge you to further investigate. We believe that once you do, you will see how continued  Covid-19 vaccine mandates jeopardize the safety of your students and the reputation of your  institution. 

The new information consists of Pfizer’s biological product file used to obtain FDA approval of  Comirnaty and data from the insurance industry showing a huge rise in excess deaths in  Millennial and Gen X populations concurrent with the implementation of vaccine approvals and  mandates. The excess death data is raising concerns in the insurance industry and on Wall Street.  We are also including timely news about product safety, given the FDA’s recent restriction of the  Johnson & Johnson vaccine due to blood clotting concerns. 

Following is a brief overview of each category and starting points for further inquiry. We are  standing by to provide you with additional information or to connect you to scientists, lawyers  and investors who are reviewing the current and evolving data. 

Pfizer Biological Product File – background and highlights:

The Public Health and Medical Professionals for Transparency (PHMPT) is a nonprofit group  made up of public health professionals, medical professionals, scientists, and journalists. The 

2  group exists solely to obtain and disseminate the data relied upon by the FDA to license  Covid-19 vaccines. Four days after the Pfizer Covid-19 vaccine was approved for children  over 16, this group submitted a Freedom of Information Act for all data within Pfizer’s  Covid-19 vaccine biological product file. When the FDA asked for 75 years to release that  data, PHMPT sued to obtain it and won. Beginning in March 2022, the public has access to  Pfizer’s clinical trial data, which is being downloaded in batches monthly. You can find the  document releases to-date here.  

Thousands of volunteers including scientists, statisticians, doctors, and lawyers continue to  examine these downloads and publish their findings. For ready reference, below are just a few of the findings of greatest concern that call into question the safety and efficacy of the Pfizer  product and support a thesis of fraud: 

o Pfizer failed the all-cause mortality endpoint in their unprecedentedly short 28- day clinical trial. In brief, more people died in the vaccinated group than in the  placebo group. This was known yet has still not been widely disclosed to the  public.  

o The CDC talking point that vaccines stopped transmission was based on no data,  as this metric was not evaluated during Pfizer’s clinical trials. Pfizer and the FDA  knew this yet did not disclose it to the public. 

o Pfizer and the FDA knew as early as November 2020 that Pfizer’s clinical trials  showed: 

▪ Vaccine failure 

▪ Waning vaccine efficacy 

A baseline condition for granting a product Emergency Use Authorization is that  it must be safe and effective. The data showed that the products are not effective.  Yet, based on FDA approval, the CDC promoted them as such. From the initial  roll-out in December 2020 through April 1, 2021, the public health messaging  was that if you received the shot, you could not get infected and could not  transmit the virus. The Pfizer documents are proof that they and the FDA colluded  to lie to the American people and the CDC created false public health narratives  based on these lies. 

o Pfizer and the FDA most likely knew in May 2021 that the vaccines caused heart  damage in teenagers based on a paper that was already in peer review at that time.  The FDA approved the product for teenagers in June 2021 yet did not disclose  this risk factor to consumers until August. During that time, all those who  received this product did not have informed consent. Parents were not made  aware of this known potential risk to their children. 

o Brook Jackson, a regional director employed by Pfizer sub-contractor Ventavia  Research Group, came forward in September 2020 with documented evidence  that the company falsified data, unblinded patients and was slow to follow up on  adverse events reported in Pfizer’s pivotal phase III trial conducted by Ventavia. 3  

Her findings call into question the integrity of not only Ventavia’s results but of  all of the results from Pfizer’s other trial sites and the entire clinical trial. Further  information is available in The British Medical Journal.

Excess death data and the insurance industry:

In December 2021, Midwest insurer One America CEO Scott Davidson disclosed a 40%  increase in excess deaths over pre-pandemic levels in the working-age (18-64) population in  the third quarter. Putting the number into context Davidson said, “The data is consistent  across every player in this business . . . Just to give you an idea of how bad that is, a three sigma or a one-in-200-year catastrophe would be a 10 percent increase over pre-pandemic.  So 40 percent is just unheard of.” Other major insurers have subsequently reported increases  in death claims ranging from 21–57 % over expected levels. Most of these deaths are not  Covid-19 deaths. Long-term disability claims are also seeing an uptick.  

These reports prompted a former institutional investor who was a #1 ranked Wall Street sell side insurance analyst to confirm the numbers using CDC reported data. His findings,  independently confirmed by others, show the spikes in excess deaths are related to the timing  of vaccine approvals and mandates. This data is prompting concern at insurance and  reinsurance companies, who will bear the financial brunt of this unexpected and  unprecedented rise in mortality. It is raising questions about the safety of the Covid-19  vaccines in the investment community and beyond. 

Of related interest is Pfizer’s amendment in February of its business risk disclosures in its Q4 2021 earnings report. The changes from the Q3 2021 report language center around  disclosures of unfavorable safety data and “further information regarding the quality of pre clinical, clinical or safety data, including by audit or inspection.”  

It is likely that neither Pfizer nor the FDA anticipated the court-compelled release of their  clinical trial and post-marketing surveillance data and the subsequent public scrutiny of it. 

Additional product safety concerns:

The FDA announced on May 5 that they were restricting use of the Johnson & Johnson  Covid-19 vaccine due to the risk of thrombosis with thrombocytopenia syndrome (TTS), a  syndrome of rare and potentially life-threatening blood clots in combination with low levels  of blood platelets. The decision to restrict was based on 60 reported cases and 9 fatalities. The  Pfizer and Moderna vaccines also have serious risks and fatalities associated with them  including but not limited to blood clots and myocarditis in college-aged populations. These  are shown in Pfizer’s post-marketing surveillance data and in the CDC’s Vaccine Adverse  Event Recording System (VAERS). As of April 29, 2022, there were approximately 1.2  million reports of adverse events following Covid-19 vaccination including more than 18,056  reports of deaths following the Pfizer vaccine, and 7,223 following the Moderna vaccine.  Logic demands that Pfizer and Moderna products be restricted immediately as well. Why  have they not been? Further, a recent Danish review of all three products in preprint in The  Lancet showed that the J&J reduced all-cause mortality but that Pfizer and Moderna did not 4  and may have increased it. Given all this, it is reasonable to think that Pfizer and Moderna  products could be restricted or discontinued very soon due to safety concerns. This might well  trigger a much higher level of scrutiny of the now-publicly available Pfizer data and the  actions of our public health institutions.

How would such a situation impact institutions such  as yours that continue to mandate the products while knowing such risks exist? 

One last thing to consider is the nature and associated secrecy of the contracts that Pfizer forced  upon governments as conditions of sale and distribution of their Covid-19 vaccines in their  respective countries. A review of some of these contracts can be found here. Terms included  such things as the waiving of sovereign immunity, countries assuming full liability in the event  that Pfizer was shown to have used another entity’s intellectual property, and that Pfizer be held  harmless in the event of injury or death from the products. Why would a company require such  terms if it knew its conduct and its products were sound? 

We trust this information has been useful and that you will investigate this matter fully. We urge  you to end your vaccine mandates to protect Princeton University’s students, reputation, and, in  the event that fraud is proven, potentially your endowment. 

Yours truly, 

No College Mandates 

No College Mandates is a coalition of thousands of concerned students, parents,  professors, staff, and community members working to end college Covid-19 vaccination  mandates and restore medical choice on college campuses. 

Health Freedom Defense Fund 

Health Freedom Defense Fund is a 501(c)(3) non-profit which seeks to protect and  advance health freedom, educate Americans on informed consent, advocate for human  rights and bodily autonomy for all people, and legally challenge unethical mandates,  laws, and policies when necessary. 

1. Deborah Prentice, Provost 

Ramona Romero, General Counsel 

Louise Sams, Board of Trustee President 

Hilary Parker, Board of Trustee Secretary 

Philip Hammarskjold, Vice Chair, Princeton Board of Trustees 

1. Goodwin, Clerk of the Board, Princeton Board of Trustees 

Amy Alving, Trustee 

Jackson Artis, Trustee 

KirstenBibbens-Domingo,Trustee 

Joshua Bolten,Trustee 

Sumir Chada, Trustee

5  

Marissa Demeo, Trustee 

Janeria Easley, Trustee 

Blair Effron, Trustee 

Henri Ford, Trustee 

Laura Forese, Trustee 

Lori Fouche, Trustee 

Heather Gerkin, Trustee 

Paul Haaga, Jr., Trustee 

Robert Hugin, Trustee 

Myesha Jemison, Trustee 

Kimberly Johnson, Trustee 

Kathy Kiely, Trustee 

Timothy Kinsgston, Trustee 

Anthony Lee, Trustee 

Paul Maeder, Trustee 

Elizabeth Myers, Trustee 

Bob Peck, Trustee 

Craig Robinson, Trustee 

Kathryn Roth-Douquet, Trustee Terri Sewell, Trustee 

Brad Smith, Trustee 

Morgan Smith, Trustee 

Sarah Stein, Trustee 

Marco Tablada, Trustee 

Sarah Varghese, Trustee 

Carla Veron, Trustee 

Melissa Wu, Trustee 

1. James Yeh, Trustee 

Anthony Yoseloff, Trustee